Condition: Advanced Solid Tumors · HNSCC · SCLC · Sponsor: Tubulis GmbH
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
This description comes directly from the study's public registry record.
Tubulis Clinical Trial Inquiries · +491758005594 · ct-inquiries@tubulis.com
Always discuss trial participation with your own doctor first.
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Mount Sinai | New York, New York, United States | Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| NEXT Oncology Austin | Austin, Texas, United States | Recruiting |
| NEXT Oncology - Dallas | Irving, Texas, United States | Recruiting |
| NEXT Oncology - San Antonio | San Antonio, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06657222